{"id":641966,"date":"2023-03-09T21:16:01","date_gmt":"2023-03-09T21:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=641966"},"modified":"2023-03-09T21:16:01","modified_gmt":"2023-03-09T21:16:01","slug":"ulcerative-colitis-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ulcerative-colitis-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_641966.html","title":{"rendered":"Ulcerative Colitis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1678365557.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ulcerative Colitis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1678365557.jpeg\" alt=\"Ulcerative Colitis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Las Vega (Nevada), United States \/\/\u2014 As per DelveInsight\u2019s assessment, globally, Ulcerative Colitis pipeline constitutes key companies continuously working towards developing Ulcerative Colitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\"><strong>Ulcerative Colitis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes the bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and becomes worse over the period of time. Ulcerative colitis is also known as inflammatory bowel disease.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Ulcerative Colitis Pipeline Insight, 2023<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ulcerative Colitis Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Ulcerative Colitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Ulcerative Colitis Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Companies across the globe are diligently working toward developing novel Ulcerative Colitis treatment therapies with a considerable amount of success over the years. Ulcerative Colitis Key players such as &#8211; <strong>NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutics, AbbVie, InDex Pharmaceuticals, Pfizer, Johnson &amp; Johnson, Takeda, Pfizer, Eli Lilly, EA Pharma, Galapagos, Bristol-Myers Squibb, Arena Pharmaceuticals<\/strong>, and others, are developing therapies for the Ulcerative Colitis treatment&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Ulcerative Colitis Emerging therapies such as &#8211; <strong>MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod<\/strong>, and others are expected to have a significant impact on the Ulcerative Colitis market in the coming years.<\/li>\n<li><strong>In November 2021, InDex Pharmaceuticals<\/strong> initiated a randomised double-blind placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Cobitolimod as an induction and maintenance therapy in participants with moderate to severe active left-sided Ulcerative Colitis&nbsp;&nbsp;&nbsp;<\/li>\n<li><strong>In March 2020, AstraZeneca<\/strong> initiated a Phase II open-label, long-term extension safety study of Brazikumab in participants with moderately to severely active Ulcerative Colitis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ulcerative Colitis Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ulcerative Colitis Assessment by Product Type<\/li>\n<li>Ulcerative Colitis By Stage and Product Type<\/li>\n<li>Ulcerative Colitis Assessment by Route of Administration<\/li>\n<li>Ulcerative Colitis By Stage and Route of Administration<\/li>\n<li>Ulcerative Colitis Assessment by Molecule Type<\/li>\n<li>Ulcerative Colitis by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Ulcerative Colitis Report covers around products under different phases of clinical development like-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Ulcerative Colitis Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>MET-2:<\/strong> NuBiyota<\/li>\n<li><strong>BT051:<\/strong> Adiso Therapeutics<\/li>\n<li><strong>NX-13:<\/strong> Landos Biopharma<\/li>\n<li><strong>PRA023:<\/strong> Prometheus Biosciences<\/li>\n<li><strong>OSE-127:<\/strong> OSE Immunotherapeutics<\/li>\n<li><strong>Brazikumab:<\/strong> AstraZeneca<\/li>\n<li><strong>MORF-057:<\/strong> Morphic Therapeutics<\/li>\n<li><strong>Risankizumab:<\/strong> AbbVie<\/li>\n<li><strong>Cobitolimod:<\/strong> InDex Pharmaceuticals<\/li>\n<li><strong>Etrasimod:<\/strong> Pfizer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Ulcerative Colitis Pipeline Therapeutic Assessment- <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Ulcerative Colitis Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Ulcerative Colitis pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.<\/li>\n<li>Ulcerative Colitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Ulcerative Colitis product details are provided in the report. Download the Ulcerative Colitis pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Ulcerative Colitis therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Ulcerative Colitis Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing awareness and R&amp;D investment<\/li>\n<li>Emergence of large number of novel pipeline molecules with great market potential<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Ulcerative Colitis Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Side effects associated with the treatment<\/li>\n<li>High cost Ulcerative Colitis treatment<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Ulcerative Colitis Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Ulcerative Colitis Companies:<\/strong> NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutics, AbbVie, InDex Pharmaceuticals, Pfizer, Johnson &amp; Johnson, Takeda, Pfizer, Eli Lilly, EA Pharma, Galapagos, Bristol-Myers Squibb, Arena Pharmaceuticals, and others<\/li>\n<li><strong>Key Ulcerative Colitis Therapies:<\/strong> MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, and others<\/li>\n<li><strong>Ulcerative Colitis Therapeutic Assessment:<\/strong> Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies<\/li>\n<li><strong>Ulcerative Colitis Market Dynamics:<\/strong> Ulcerative Colitis market drivers and Ulcerative Colitis market barriers&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Ulcerative Colitis Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis- Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Late Stage Products (Phase II\/III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Preclinical Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Therapeutics Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12<\/p>\n<\/td>\n<td>\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16&nbsp;<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18<\/p>\n<\/td>\n<td>\n<p>Ulcerative Colitis Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Ulcerative Colitis drugs and therapies<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ulcerative-colitis-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ulcerative-colitis-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Las Vega (Nevada), United States \/\/\u2014 As per DelveInsight\u2019s assessment, globally, Ulcerative Colitis pipeline constitutes key companies continuously working towards developing Ulcerative Colitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ulcerative-colitis-pipeline-drugs-and-companies-insight-report-2023-updates-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_641966.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-641966","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/641966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=641966"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/641966\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=641966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=641966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=641966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}